Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Reply to comment: Empirical antibiotic therapy for patients with SBP and ACLF - Need for rapid decision.

Wieser A, Li H, Suerbaum S, Mayerle J, Gerbes AL, Steib CJ.

Dig Liver Dis. 2019 Nov 13. pii: S1590-8658(19)30828-X. doi: 10.1016/j.dld.2019.09.010. [Epub ahead of print] No abstract available.

PMID:
31734111
2.

Liver transplantation in patients with a history of migration-A German single center comparative analysis.

Bucher JN, Koenig M, Schoenberg MB, Crispin A, Thomas M, Angele MK, Eser-Valeri D, Gerbes AL, Werner J, Guba MO.

PLoS One. 2019 Oct 22;14(10):e0224116. doi: 10.1371/journal.pone.0224116. eCollection 2019.

3.

Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model.

Reiter FP, Ye L, Bösch F, Wimmer R, Artmann R, Ziesch A, Kanitz V, Mayr D, Steib CJ, Trauner M, Regel I, Gerbes AL, Mayerle J, Hohenester S, de Toni EN, Denk G.

Lab Invest. 2019 Dec;99(12):1906-1917. doi: 10.1038/s41374-019-0310-1. Epub 2019 Aug 29.

PMID:
31467426
4.

Drug-Drug Combinations can Enhance Toxicity as shown by Monocyte-Derived Hepatocyte-like Cells from Patients with Idiosyncratic Drug-Induced Liver Injury.

Benesic A, Jalal K, Gerbes AL.

Toxicol Sci. 2019 Aug 12. pii: kfz156. doi: 10.1093/toxsci/kfz156. [Epub ahead of print]

PMID:
31407002
5.

The effects of hepatic steatosis on thromboxane A2 induced portal hypertension.

Zhang J, Schewe J, Li H, Makeschin MC, Mahajan UM, Gerbes AL, Steib CJ.

Gastroenterol Hepatol. 2019 Nov;42(9):534-541. doi: 10.1016/j.gastrohep.2019.03.015. Epub 2019 Jul 17. English, Spanish.

PMID:
31326104
6.

Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.

Weber S, Benesic A, Rotter I, Gerbes AL.

Liver Int. 2019 Oct;39(10):1906-1917. doi: 10.1111/liv.14195. Epub 2019 Aug 5.

PMID:
31319011
7.

Ischemic Postconditioning (IPostC) Protects Fibrotic and Cirrhotic Rat Livers after Warm Ischemia.

Schewe J, Makeschin MC, Liss I, Mayr D, Zhang J, Khandoga A, Rothenfußer S, Schnurr M, Gerbes AL, Steib CJ.

Can J Gastroenterol Hepatol. 2019 Jun 9;2019:5683479. doi: 10.1155/2019/5683479. eCollection 2019.

8.

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.

Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN.

Cell Oncol (Dordr). 2019 Oct;42(5):705-715. doi: 10.1007/s13402-019-00458-8. Epub 2019 Jun 27.

PMID:
31250364
9.

Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality.

Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, Henker R, Berg T, Maidhof HP, Trauer H, Wiegand J.

Am J Gastroenterol. 2019 Aug;114(8):1358-1359. doi: 10.14309/ajg.0000000000000300. No abstract available.

PMID:
31246695
10.

[Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)].

Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gülberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV); Deutsche Gesellschaft für Innere Medizin e. V. (DGIM); Deutsche Gesellschaft für Infektiologie e. V. (DGI); Deutsche Gesellschaft für Pathologie e. V./Bundesverband deutscher Pathologen e. V. (DGP/BDP); Deutsche Röntgengesellschaft e. V. (DRG); Deutsche Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR); Deutsche Gesellschaft für Nephrologie (DGFN); Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Neurologie e. V. (DGN); Deutsche Gesellschaft für Ernährungsmedizin e. V. (DGEM); Lebertransplantierte Deutschland e. V; Collaborators:.

Z Gastroenterol. 2019 May;57(5):e168. doi: 10.1055/a-0928-2800. Epub 2019 May 24. German. No abstract available.

PMID:
31127596
11.

Leitlinie Komplikationen der Leberzirrhose.

Gerbes AL, Labenz J.

Z Gastroenterol. 2019 May;57(5):571-573. doi: 10.1055/a-0873-4641. Epub 2019 May 13. German. No abstract available.

PMID:
31083745
12.

Leitlinienreport zur aktualisierten S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zu Komplikationen der Leberzirrhose.

Lynen Jansen P, Gerbes AL, Labenz J, Jungnitsch J, van Leeuwen P.

Z Gastroenterol. 2019 May;57(5):e121-e129. doi: 10.1055/a-0873-4682. Epub 2019 May 13. German. No abstract available.

PMID:
31083744
Free Article
13.

[Updated S2k-Guideline "Complications of liver cirrhosis". German Society of Gastroenterology (DGVS)].

Gerbes AL, Labenz J, Appenrodt B, Dollinger M, Gundling F, Gülberg V, Holstege A, Lynen-Jansen P, Steib CJ, Trebicka J, Wiest R, Zipprich A; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV); Deutsche Gesellschaft für Innere Medizin e. V. (DGIM); Deutsche Gesellschaft für Infektiologie e. V. (DGI); Deutsche Gesellschaft für Pathologie e. V./Bundesverband deutscher Pathologen e. V. (DGP/BDP); Deutsche Röntgengesellschaft e. V. (DRG); Deutsche Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR); Deutsche Gesellschaft für Nephrologie (DGFN); Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Neurologie e. V. (DGN); Deutsche Gesellschaft für Ernährungsmedizin e. V. (DGEM); Lebertransplantierte Deutschland e. V; Collaborators:.

Z Gastroenterol. 2019 May;57(5):611-680. doi: 10.1055/a-0873-4658. Epub 2019 May 6. German. Erratum in: Z Gastroenterol. 2019 May;57(5):e168.

14.

Acute Liver Failure During Pirfenidone Treatment Triggered by Co-Medication With Esomeprazole.

Benesic A, Jalal K, Gerbes AL.

Hepatology. 2019 Nov;70(5):1869-1871. doi: 10.1002/hep.30684. Epub 2019 Jun 28. No abstract available.

PMID:
31034631
15.

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.

Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN.

Cell Death Discov. 2019 Apr 5;5:86. doi: 10.1038/s41420-019-0165-7. eCollection 2019.

16.

Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis.

Wieser A, Li H, Zhang J, Liss I, Markwardt D, Hornung R, Suerbaum S, Mayerle J, Gerbes AL, Steib CJ.

Dig Liver Dis. 2019 Sep;51(9):1300-1307. doi: 10.1016/j.dld.2019.02.015. Epub 2019 Mar 31.

PMID:
30944073
17.

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.

De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J.

Gut. 2020 Jan;69(1):168-176. doi: 10.1136/gutjnl-2018-318193. Epub 2019 Mar 16.

18.

The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.

Op den Winkel M, Nagel D, Op den Winkel P, Paprottka PM, Schmidt L, Bourhis H, Trojan J, Goeller M, Reiter FP, Stecher SS, De Toni EN, Gerbes AL, Kolligs FT.

Digestion. 2019;100(1):15-26. doi: 10.1159/000493136. Epub 2018 Oct 3.

PMID:
30282074
19.

Proteomics Analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac.

Dragoi D, Benesic A, Pichler G, Kulak NA, Bartsch HS, Gerbes AL.

Front Pharmacol. 2018 Jul 4;9:699. doi: 10.3389/fphar.2018.00699. eCollection 2018.

20.

Herbal tea and liver injury - Tea extract or comedication can make a difference.

Benesic A, Gerbes AL.

J Hepatol. 2018 Aug;69(2):547-548. doi: 10.1016/j.jhep.2018.03.033. No abstract available.

PMID:
29776714
21.

Development and Validation of a Test to Identify Drugs That Cause Idiosyncratic Drug-Induced Liver Injury.

Benesic A, Rotter I, Dragoi D, Weber S, Buchholtz ML, Gerbes AL.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1488-1494.e5. doi: 10.1016/j.cgh.2018.04.049. Epub 2018 Apr 30. Erratum in: Clin Gastroenterol Hepatol. 2019 Apr;17(5):1008.

PMID:
29723689
22.

Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.

Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT.

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):44-53. doi: 10.1097/MEG.0000000000001005.

PMID:
29076939
23.

Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6-24 weeks.

Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.

Data Brief. 2017 Sep 18;15:163-169. doi: 10.1016/j.dib.2017.09.019. eCollection 2017 Dec.

24.

Cell death markers in patients with cirrhosis and acute decompensation.

Macdonald S, Andreola F, Bachtiger P, Amoros A, Pavesi M, Mookerjee R, Zheng YB, Gronbaek H, Gerbes AL, Sola E, Caraceni P, Moreau R, Gines P, Arroyo V, Jalan R.

Hepatology. 2018 Mar;67(3):989-1002. doi: 10.1002/hep.29581. Epub 2018 Jan 24.

25.

Mitochondrial adaptation in steatotic mice.

Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.

Mitochondrion. 2018 May;40:1-12. doi: 10.1016/j.mito.2017.08.015. Epub 2017 Sep 19.

PMID:
28935446
26.

Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.

Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, Moreau R, Teupser D, Wendon J, Nevens F, Trebicka J, Garcia E, Pavesi M, Arroyo V, Gerbes AL.

Hepatology. 2017 Oct;66(4):1232-1241. doi: 10.1002/hep.29290. Epub 2017 Aug 26.

PMID:
28545169
27.

Tapering of Immunosuppression and Sustained Treatment With Nivolumab in a Liver Transplant Recipient.

De Toni EN, Gerbes AL.

Gastroenterology. 2017 May;152(6):1631-1633. doi: 10.1053/j.gastro.2017.01.063. Epub 2017 Apr 4. No abstract available.

PMID:
28384452
28.

Drug-induced liver injury: recent advances in diagnosis and risk assessment.

Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP.

Gut. 2017 Jun;66(6):1154-1164. doi: 10.1136/gutjnl-2016-313369. Epub 2017 Mar 23. Review.

29.

Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.

Steib CJ, Gerbes AL.

Hepatol Int. 2017 Mar;11(2):141-142. doi: 10.1007/s12072-017-9791-4. Epub 2017 Feb 23. No abstract available.

PMID:
28233256
30.

Diagnosis and treatment of ascites.

Tsochatzis EA, Gerbes AL.

J Hepatol. 2017 Jul;67(1):184-185. doi: 10.1016/j.jhep.2017.01.011. Epub 2017 Jan 22. No abstract available.

PMID:
28119010
31.

Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis.

Huang L, Crino M, Wu JH, Woodward M, Land MA, McLean R, Webster J, Enkhtungalag B, Nowson CA, Elliott P, Cogswell M, Toft U, Mill JG, Furlanetto TW, Ilich JZ, Hong YH, Cohall D, Luzardo L, Noboa O, Holm E, Gerbes AL, Senousy B, Pinar Kara S, Brewster LM, Ueshima H, Subramanian S, Teo BW, Allen N, Choudhury SR, Polonia J, Yasuda Y, Campbell NR, Neal B, Petersen KS.

JMIR Res Protoc. 2016 Sep 21;5(3):e190. doi: 10.2196/resprot.6282.

32.

Liver Cirrhosis and Kidney.

Gerbes AL.

Dig Dis. 2016;34(4):387-90. doi: 10.1159/000444553. Epub 2016 May 11.

PMID:
27170393
33.

Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.

Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU.

World J Hepatol. 2016 Mar 18;8(8):401-10. doi: 10.4254/wjh.v8.i8.401.

34.

Automated low flow pump system for the treatment of refractory ascites: a single-center experience.

Thomas MN, Sauter GH, Gerbes AL, Stangl M, Schiergens TS, Angele M, Werner J, Guba M.

Langenbecks Arch Surg. 2015 Dec;400(8):979-83. doi: 10.1007/s00423-015-1356-1. Epub 2015 Nov 13.

PMID:
26566989
35.

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.

Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.

36.

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN.

Oncotarget. 2015 Sep 8;6(26):22167-78.

37.

Infection as a Trigger for Portal Hypertension.

Steib CJ, Schewe J, Gerbes AL.

Dig Dis. 2015;33(4):570-6. doi: 10.1159/000375352. Epub 2015 Jul 6.

PMID:
26159275
38.

Drug-Induced Liver Injury and Individual Cell Models.

Benesic A, Gerbes AL.

Dig Dis. 2015;33(4):486-91. doi: 10.1159/000374094. Epub 2015 Jul 6.

PMID:
26159263
39.

The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis. Preface.

Gerbes AL, Jaeschke H.

Dig Dis. 2015;33(4):457. doi: 10.1159/000375478. Epub 2015 Jul 6. No abstract available.

PMID:
26159258
40.

Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury.

Benesic A, Leitl A, Gerbes AL.

Gut. 2016 Sep;65(9):1555-63. doi: 10.1136/gutjnl-2015-309528. Epub 2015 Jun 4.

PMID:
26045135
41.

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.

Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM.

J Hepatol. 2015 Jul;63(1):102-13. doi: 10.1016/j.jhep.2015.01.031. Epub 2015 Feb 7.

PMID:
25660209
42.

The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.

Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Ginès P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V; CANONIC Study Investigators; EASL-CLIF Consortium.

J Hepatol. 2015 Apr;62(4):831-40. doi: 10.1016/j.jhep.2014.11.012. Epub 2014 Nov 22. Erratum in: J Hepatol. 2015 Jul;63(1):291.

43.

Role of cysteinyl-leukotrienes for portal pressure regulation and liver damage in cholestatic rat livers.

op den Winkel M, Gmelin L, Schewe J, Leistner N, Bilzer M, Göke B, Gerbes AL, Steib CJ.

Lab Invest. 2013 Dec;93(12):1288-94. doi: 10.1038/labinvest.2013.115. Epub 2013 Sep 23.

44.

Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension.

Steib CJ, Gmelin L, Pfeiler S, Schewe J, Brand S, Göke B, Gerbes AL.

Life Sci. 2013 Oct 11;93(16):543-51. doi: 10.1016/j.lfs.2013.08.018. Epub 2013 Sep 3.

PMID:
24007798
45.

Portal pressure regulation following Kupffer cell activation: control of prostaglandin production by heme oxygenases.

Steib CJ, Gmelin L, Bilzer M, Göke B, Gerbes AL.

Digestion. 2013;87(2):102-9. doi: 10.1159/000345145. Epub 2013 Jan 16.

PMID:
23327898
46.

The impact of acute kidney injury in cirrhosis: does definition matter?

Gerbes AL.

Gut. 2013 Jul;62(7):1091. doi: 10.1136/gutjnl-2012-304378. Epub 2013 Jan 11. No abstract available.

PMID:
23315501
47.

High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.

Hinz M, Wree A, Jochum C, Bechmann LP, Saner F, Gerbes AL, Gerken G, Canbay A.

Ann Hepatol. 2013 Jan-Feb;12(1):92-9.

48.

Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

Kriegl L, Jung A, Horst D, Rizzani A, Jackstadt R, Hermeking H, Gallmeier E, Gerbes AL, Kirchner T, Göke B, De Toni EN.

PLoS One. 2012;7(12):e51654. doi: 10.1371/journal.pone.0051654. Epub 2012 Dec 20.

49.

Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies.

Benesic A, Rahm NL, Ernst S, Gerbes AL.

Lab Invest. 2012 Jun;92(6):926-36. doi: 10.1038/labinvest.2012.64. Epub 2012 Apr 2.

50.

[Method report: German S3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome"].

Gerbes AL, Sauerbruch T, Dathe K.

Z Gastroenterol. 2011 Jun;49(6):780-7. doi: 10.1055/s-0031-1273404. Epub 2011 Jun 1. German. No abstract available.

PMID:
21638243

Supplemental Content

Loading ...
Support Center